Lymphoma News

Nanomedicine has been a promising area of clinical research — particularly in the cancer setting — for decades, and experts said its potential has only increased with advances in cancer diagnostics and therapeutics.

CHICAGO — Combining brentuximab vedotin with a chemotherapy regimen as first-line therapy conferred an objective response in 88% of younger patients with newly diagnosed advanced-stage classical Hodgkin lymphoma, study results show.

In its 2022 Cancer Disparities Progress Report, American Association for Cancer Research discussed advances made in closing substantial gaps in care while underscoring the need for further progress.

CHICAGO — The addition of daratumumab to chemotherapy improved outcomes among younger patients with relapsed or refractory T-cell acute lymphoblastic leukemia, study results showed.

CHICAGO — Patients and prescribers should be more aware of the potential for major adverse cardiac events after immune checkpoint inhibitor-based therapy, according to retrospective study results presented at ASCO Annual Meeting.

CHICAGO — During the ASCO Annual Meeting, Healio honored our inaugural Healio Disruptive Innovators in hematology/oncology.

CHICAGO — Axicabtagene ciloleucel exhibited comparable efficacy and safety for large B-cell lymphoma regardless of patients’ race or ethnicity, according to study results presented at ASCO Annual Meeting.

CHICAGO — The addition of brentuximab vedotin to frontline chemotherapy significantly extended OS among patients with advanced classical Hodgkin lymphoma, according to study results presented at ASCO Annual Meeting.

CHICAGO — A novel first-line regimen significantly improved PFS compared with standard chemoimmunotherapy for older patients with mantle cell lymphoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.

With new developments in the treatment of follicular lymphoma, such as chimeric antigen receptor T-cell therapies, whether the traditional watch-and-wait approach remains acceptable has been thrown into question.